April 8, 2015 – Wuhan YZY biopharma holds the corner stone laying ceremony for its biopharma manufacturing facility at biolake biopharma industry park of the optical valley in Donghu New Technology Development Zone. Honghao Zhou, an academician of Chinese Academy of Engineering and a pioneer of pharmacogenetics and personalized medicine in China, and Deping Qian, deputy director of construction management office for Wuhan national biological industry base, and other guests and leaders attended the ceremony.
Wuhan YZY biopharma is one of the key enterprises of biolake of the optical valley. Since its establishment in the biolake biopharma industry park in 2001, adhering to innovation and developing therapeutic drugs for cancer, Wuhan YZY biopharma is growing prosperously. The company has developed a series of internationally innovative drugs using its patented bispecific antibody technologies. Its drug development projects are supported by “China National Essential Drug Development Program”.
Wuhan YZY biopharma plans to invest 260 million Yuan for construction of the bispecific antibody manufacturing facility. The manufacturing facility will have four large-scale mammalian cell culture lines, two purification production lines and one filling and finishing line. After the construction is completed,the manufacturing facility will meet the demands for manufacturing of the company’s bispecific drugs and will lay the foundation of commercialization of these bispecifics.